Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) treated with osimertinib (osi) vs. Afatinib or erlotinib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) treated with osimertinib (osi) vs. Afatinib or erlotinib

Published:2024-09 Issue: Volume:195 Page:107926
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Barsouk Adam^ORCID,Elghawy Omar^ORCID,Heidlauf Alec,Yu Connie,Wang Lucy^ORCID,Yang David^ORCID,Kurian Martin^ORCID,Goel Keshav^ORCID,Rushkin Lynn,Anran Huang Anna,Reed-Guy Lauren^ORCID,Bleiberg Benjamin^ORCID,Sun Lova,Singh Aditi^ORCID,Cohen Roger B.,Aggarwal Charu,Marmarelis Melina^ORCID,Langer Corey

Publisher

Elsevier BV

Reference12 articles.

1. Epidemiology of lung cancer;Thandra;Contemp Oncol.,2021

2. Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC;Ramalingam;New England Journal of Medicine.,2020

3. Various Subtypes of EGFR Mutations in Patients With NSCLC Define Genetic, Immunologic Diversity and Possess Different Prognostic Biomarkers;Lei;Front Immunol.,2022

4. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6;Yang;Lancet Oncol.,2015

5. Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis;Wang;Oncologist.,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP